Base de dados : MEDLINE
Pesquisa : D27.505.954.016 [Categoria DeCS]
Referências encontradas : 4360 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 436 ir para página                         

  1 / 4360 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29262451
[Au] Autor:Chen XQ; Ma Q; Zhou LY; Ma HA; Wu JY; Zhao JJ; Yan DN
[Ad] Endereço:Department of Otorhinolaryngology, Affiliated Hospital of Nanjing University of TCM, Nanjing 210029, China.
[Ti] Título:[Experimental study on the effect of Yiqi Wenyang Decoction on nasal mucosa infiltration of NK cells in mice with allergic rhinitis].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;52(12):921-926, 2017 Dec 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To observe the effect of Yiqi Wenyang Decoction on the infiltration and activation of NK cells in nasal mucosa of mouse model with allergic rhinitis (AR), and to explore the potential mechanism for effective intervention of AR with Yiqi Wenyang Decoction. Fourty-eight mice were randomly divided into blank group, model group, low, medium and high dose of Yiqi Wenyang Decoction group and Cetirizine group, with 8 rats in each group. After modeling of AR, the model group was filled with 0.9% sodium chloride solution. Yiqi Wenyang Decoction groups of each dose were given different concentrations of Yiqi Wenyang Decoction water extract, while the Cetirizine group was given aqueous solution of Cetirizine. The behavior, morphological changes of nasal mucosa and infiltration of NK cells in nasal mucosa were observed. The levels of IL-4 and INF-γ in nasal lavage fluid were measured. Besides, the drug safety was observed by acute toxicity test. In the respect of behavioral scoring, middle and high dose of Yiqi Wenyang Decoction group were superior to the model group (number of sneezing: value was 7.189, 8.748, respectively; number of scratching nose: value was 12.074, 14.560, respectively; all <0.05). In middle and high dose of Yiqi Wenyang Decoction group, the infiltration of NK cells and nasal lavage fluid IL-4 levels were lower than those in model group (IOD: value was 10.073, 12.322, respectively; IOD/Area: value was 10.954, 14.073, respectively; IL-4: value was 4.705, 6.801, respectively; all <0.05). There was no significant difference in nasal lavage fluid of INF-γ among each group ( =1.166, >0.05). In acute toxicity test, no obvious poisoning symptoms and death occurred in mice. Yiqi Wenyang Decoction can control the nasal symptom, reduce the local NK cell infiltration of nasal mucosa and inhibit the expression of the 2-type cytokines released by NK cells, which may be related with the potential mechanism of effective intervention of AR with Yiqi Wenyang Decoction.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/uso terapêutico
Células Matadoras Naturais/efeitos dos fármacos
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antialérgicos/efeitos adversos
Antialérgicos/uso terapêutico
Cetirizina/efeitos adversos
Cetirizina/uso terapêutico
Modelos Animais de Doenças
Medicamentos de Ervas Chinesas/efeitos adversos
Interferon gama/análise
Interleucina-4/análise
Camundongos
Líquido da Lavagem Nasal/química
Mucosa Nasal/citologia
Mucosa Nasal/imunologia
Distribuição Aleatória
Rinite Alérgica/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Drugs, Chinese Herbal); 207137-56-2 (Interleukin-4); 82115-62-6 (Interferon-gamma); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2017.12.009


  2 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452145
[Au] Autor:Rutkowski K; Grattan CEH
[Ad] Endereço:Urticaria Clinic, St John's Institute of Dermatology, London, UK.
[Ti] Título:How to manage chronic urticaria 'beyond' guidelines: a practical algorithm.
[So] Source:Clin Exp Allergy;47(6):710-718, 2017 Jun.
[Is] ISSN:1365-2222
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chronic urticaria (CU) is a disease characterized by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Omalizumab, an anti-immunoglobulin E monoclonal antibody, has transformed the management of many severe and treatment-refractory patients. However, current UK guidance on its use does not address the needs of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema without weals as a presentation of CU and omalizumab non-responders. Our algorithm and a summary of the evidence to support its principles offers guidance and a more systematic targeted approach to using a range of 'off-label' agents for specific phenotypes of CU. It will be of use when guideline-recommended mast cell mediator antagonists fail to control symptoms and/or using omalizumab is ineffective, not practical or unfunded.
[Mh] Termos MeSH primário: Algoritmos
Antialérgicos/uso terapêutico
Urticária/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Crônica/tratamento farmacológico
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Allergic Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/cea.12944


  3 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802371
[Au] Autor:Ocak E; Kocaoz D; Acar B
[Ad] Endereço:Department of Otorhinolaryngology, Kecioren Research and Training Hospital, Ankara, Turkey.
[Ti] Título:How can we improve medical adherence to intranasal corticosteroids in children?
[So] Source:Int J Pediatr Otorhinolaryngol;100:194-197, 2017 Sep.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the factors which may be related to nonadherence to intranasal corticosteroids (ICS) in the treatment of allergic rhinitis (AR) in children. METHODS: A prospective study was conducted on children with AR diagnosis in a tertiary referral hospital. All participants were provided with mometasone furoate nasal sprays for 30 days after the diagnosis. Caregivers were called back when the therapy was over and completed a questionnaire about the factors that may influence the adherence to the treatment. Afterwards each caregiver completed the Turkish language validated Morisky Medical Adherence Scale (MMAS-8) form. Each factor was evaluated according to MMAS-8 score and all variables were analyzed statistically. RESULTS: A total number of 76 children with a mean age of 7.82 years were included in the study. The mean overall MMAS-8 score was 2.80. There was only one factor significantly related to low adherence; the number of dependent children to the caregiver (p = 0.011). Besides this 71.51% of the answers to MMAS-8 scale were compatible with good adherence. CONCLUSION: The clinician must consider the factors which may lead to non-adherence while setting up a treatment plan. The demographic and sociocultural factors must be taken into consideration and treatment schedule should be made in respect of daily activities of the children. Moreover the father can be involved in the therapy plan and back up the mother as they are usually the responsible parent for children's medical therapy.
[Mh] Termos MeSH primário: Antialérgicos/administração & dosagem
Glucocorticoides/administração & dosagem
Adesão à Medicação
Furoato de Mometasona/administração & dosagem
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intranasal
Criança
Feminino
Seres Humanos
Masculino
Sprays Nasais
Estudos Prospectivos
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Glucocorticoids); 0 (Nasal Sprays); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170814
[St] Status:MEDLINE


  4 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28692272
[Au] Autor:Niu S; Fan ZW; Xie CL; Liu Q; Luo ZH; Liu G; Yang XW
[Ad] Endereço:State Key Laboratory Breeding Base of Marine Genetic Resources, Key Laboratory of Marine Genetic Resources, Fujian Key Laboratory of Marine Genetic Resources, South China Sea Bio-Resource Exploitation and Utilization Collaborative Innovation Center, Third Institute of Oceanography, State Oceanic Adm
[Ti] Título:Spirograterpene A, a Tetracyclic Spiro-Diterpene with a Fused 5/5/5/5 Ring System from the Deep-Sea-Derived Fungus Penicillium granulatum MCCC 3A00475.
[So] Source:J Nat Prod;80(7):2174-2177, 2017 Jul 28.
[Is] ISSN:1520-6025
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A novel spiro-tetracyclic diterpene, spirograterpene A (1), was isolated from the deep-sea-derived fungus Penicillium granulatum MCCC 3A00475, together with two biosynthetically related cyclopianes, conidiogenone I (2) and conidiogenone C (3). The relative configuration of 1 was elucidated by extensive spectroscopic analyses, and the absolute structure was established by the modified Mosher's method. Compound 1 is the second example of a diterpene featuring a 5/5/5/5 spirocyclic carbon skeleton. It showed modest antiallergic activity.
[Mh] Termos MeSH primário: Antialérgicos/isolamento & purificação
Diterpenos/isolamento & purificação
Penicillium/química
[Mh] Termos MeSH secundário: Antialérgicos/química
Antialérgicos/farmacologia
Diterpenos/química
Diterpenos/farmacologia
Biologia Marinha
Estrutura Molecular
Compostos de Espiro
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Diterpenes); 0 (Spiro Compounds); 0 (conidiogenone I); 0 (spirograterpene A)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jnatprod.7b00475


  5 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28659489
[Au] Autor:Morrison J; Rathore APS; Mantri CK; Aman SAB; Nishida A; St John AL
[Ad] Endereço:Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, New York, USA jmm2105@cumc.columbia.edu ashley.st.john@duke-nus.edu.sg.
[Ti] Título:Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model.
[So] Source:J Virol;91(18), 2017 Sep 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There are no approved therapeutics for the treatment of dengue disease despite the global prevalence of dengue virus (DENV) and its mosquito vectors. DENV infections can lead to vascular complications, hemorrhage, and shock due to the ability of DENV to infect a variety of immune and nonimmune cell populations. Increasingly, studies have implicated the host response as a major contributor to severe disease. Inflammatory products of various cell types, including responding T cells, mast cells (MCs), and infected monocytes, can contribute to immune pathology. In this study, we show that the host response to DENV infection in immunocompetent mice recapitulates transcriptional changes that have been described in human studies. We found that DENV infection strongly induced metabolic dysregulation, complement signaling, and inflammation. DENV also affected the immune cell content of the spleen and liver, enhancing NK, NKT, and CD8 T cell activation. The MC-stabilizing drug ketotifen reversed many of these responses without suppressing memory T cell formation and induced additional changes in the transcriptome and immune cell composition of the spleen, consistent with reduced inflammation. This study provides a global transcriptional map of immune activation in DENV target organs of an immunocompetent host and supports the further development of targeted immunomodulatory strategies to treat DENV disease. Dengue virus (DENV), which causes febrile illness, is transmitted by mosquito vectors throughout tropical and subtropical regions of the world. Symptoms of DENV infection involve damage to blood vessels and, in rare cases, hemorrhage and shock. Currently, there are no targeted therapies to treat DENV infection, but it is thought that drugs that target the host immune response may be effective in limiting symptoms that result from excessive inflammation. In this study, we measured the host transcriptional response to infection in multiple DENV target organs using a mouse model of disease. We found that DENV infection induced metabolic dysregulation and inflammatory responses and affected the immune cell content of the spleen and liver. The use of the mast cell stabilization drug ketotifen reversed many of these responses and induced additional changes in the transcriptome and immune cell repertoire that contribute to decreased dengue disease.
[Mh] Termos MeSH primário: Antialérgicos/administração & dosagem
Vírus da Dengue/imunologia
Dengue/tratamento farmacológico
Dengue/patologia
Perfilação da Expressão Gênica
Cetotifeno/administração & dosagem
Mastócitos/imunologia
[Mh] Termos MeSH secundário: Animais
Dengue/imunologia
Modelos Animais de Doenças
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); X49220T18G (Ketotifen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE


  6 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28656804
[Au] Autor:Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F
[Ad] Endereço:a Division of Allergy and Clinical Immunology, Department of Medicine , East Tennessee Statement , Johnson City , TN , USA.
[Ti] Título:Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.
[So] Source:Expert Opin Pharmacother;18(11):1137-1143, 2017 Aug.
[Is] ISSN:1744-7666
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Olopatadine hydrochloride is an antihistamine and mast cell stabilizer available as oral, intranasal and ocular preparations. Most of the practical applications of olopatadine therapy focus on the treatment of allergic rhinoconjunctivitis via intranasal and ocular routes. Areas covered: This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of children and adults. The articles that have been selected, evaluate the use of intranasal and ocular antihistamines and their role in allergic rhinoconjunctivitis. Expert opinion: Olopatadine is significantly more effective than placebos in relieving the symptoms of allergic rhinoconjunctivitis. It can function both as a viable alternative or addition to first line therapies such as intranasal steroids and oral antihistamines.
[Mh] Termos MeSH primário: Antialérgicos/uso terapêutico
Conjuntivite Alérgica/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Cloridrato de Olopatadina/uso terapêutico
[Mh] Termos MeSH secundário: Administração Intranasal
Administração Oftálmica
Administração Oral
Adulto
Antialérgicos/administração & dosagem
Antialérgicos/efeitos adversos
Ensaios Clínicos como Assunto
Antagonistas dos Receptores Histamínicos H1/administração & dosagem
Antagonistas dos Receptores Histamínicos H1/efeitos adversos
Seres Humanos
Cloridrato de Olopatadina/administração & dosagem
Cloridrato de Olopatadina/efeitos adversos
Cloridrato de Olopatadina/farmacocinética
Soluções Oftálmicas/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Histamine H1 Antagonists); 0 (Ophthalmic Solutions); 2XG66W44KF (Olopatadine Hydrochloride)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1080/14656566.2017.1346085


  7 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28647457
[Au] Autor:Vigl B; Salhat N; Parth M; Pankevych H; Mairhofer A; Bartl S; Smrzka OW
[Ad] Endereço:AFFiRiS AG, Karl-Farkas-Gasse 22, 1030 Vienna, Austria. Electronic address: benjamin.vigl@affiris.com.
[Ti] Título:Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies.
[So] Source:J Immunol Methods;449:28-36, 2017 Oct.
[Is] ISSN:1872-7905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Targeting plasma IgE by therapeutic mABs like Omalizumab (Xolair ) is current clinical practice for severe allergic conditions or other IgE related diseases like chronic urticaria. As an alternative to soluble IgE targeting, IgE supply can be lowered by targeting the Extracellular Membrane Proximal Domain (EMPD) of the IgE B cell receptor (BCR) present on IgE switched B cells. This ultimately leads to apoptosis of these cells upon IgE BCR crosslinking. Since tools to selectively assess the efficacy of IgE BCR crosslinking by IgE targeting antibodies are limited, a readily quantifiable cell model was developed that allows to specifically address IgE BCR crosslinking activity in vitro. The new cell model allowed for a direct quantitative comparison of anti-EMPD IgE therapeutic prototype antibody 47H4 with anti-IgE(Ce3) directed therapeutic antibody Omalizumab and with a newly selected anti-human EMPD IgE monoclonal antibody, designated mAB 15cl12. Furthermore, a complementing mouse model was developed that allows for in vivo validation of antibodies addressing human EMPD IgE. It carries a targetable humanized EMPD IgE sequence that has been introduced by seamless genomic replacement of the endogenous EMPD encoding sequence. The model allowed to directly compare IgE lowering activity of two anti-human EMPD IgE therapeutic antibodies in vivo. Our tools provide the means for quantitative assessment of IgE BCR crosslinking activity which is increasingly gaining attention with respect to forthcoming second generation anti-IgE clinical candidates such as Ligelizumab or other clinical candidates featuring additional effector functions such as IgE BCR crosslinking activity.
[Mh] Termos MeSH primário: Anticorpos Anti-Idiotípicos/imunologia
Imunoglobulina E/química
Imunoglobulina E/imunologia
Receptores de Antígenos de Linfócitos B/química
Receptores de Antígenos de Linfócitos B/imunologia
[Mh] Termos MeSH secundário: Animais
Antialérgicos/química
Antialérgicos/metabolismo
Anticorpos Anti-Idiotípicos/química
Anticorpos Anti-Idiotípicos/metabolismo
Reagentes para Ligações Cruzadas
Seres Humanos
Imunoglobulina E/biossíntese
Imunoglobulina E/metabolismo
Camundongos
Omalizumab/química
Omalizumab/metabolismo
Receptores de Antígenos de Linfócitos B/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Antibodies, Anti-Idiotypic); 0 (Cross-Linking Reagents); 0 (Receptors, Antigen, B-Cell); 0 (anti-IgE antibodies); 2P471X1Z11 (Omalizumab); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170626
[St] Status:MEDLINE


  8 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28646023
[Au] Autor:Tamai H; Yamaguchi H; Miyake K; Takatori M; Kitano T; Yamanaka S; Yui S; Fukunaga K; Nakayama K; Inokuchi K
[Ad] Endereço:Department of Hematology, Nippon Medical School, Tokyo, Japan. s6056@nms.ac.jp.
[Ti] Título:Amlexanox Downregulates S100A6 to Sensitize -Positive Acute Lymphoblastic Leukemia to TNFα Treatment.
[So] Source:Cancer Res;77(16):4426-4433, 2017 Aug 15.
[Is] ISSN:1538-7445
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acute lymphoblastic leukemias (ALL) positive for ( ) translocation, which constitute 60% of all infant ALL cases, have a poor prognosis even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This poor prognosis is due to one of two factors, either resistance to TNFα, which mediates a graft-versus-leukemia (GVL) response after allo-HSCT, or immune resistance due to upregulated expression of the immune escape factor S100A6. Here, we report an immune stimulatory effect against -positive ALL cells by treatment with the anti-allergy drug amlexanox, which we found to inhibit S100A6 expression in the presence of TNF-α. In -positive transgenic (Tg) mice, amlexanox enhanced tumor immunity and lowered the penetrance of leukemia development. Similarly, in a NOD/SCID mouse model of human -positive ALL, amlexanox broadened GVL responses and extended survival. Our findings show how amlexanox degrades the resistance of -positive ALL to TNFα by downregulating S100A6 expression, with immediate potential implications for improving clinical management of -positive ALL. .
[Mh] Termos MeSH primário: Aminopiridinas/farmacologia
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia
Proteínas de Ciclo Celular/metabolismo
Proteínas de Ligação a DNA/metabolismo
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
Proteínas S100/metabolismo
Fatores de Elongação da Transcrição/metabolismo
Fator de Necrose Tumoral alfa/farmacologia
[Mh] Termos MeSH secundário: Animais
Antialérgicos/administração & dosagem
Antialérgicos/farmacologia
Proteínas de Ciclo Celular/genética
Proteínas de Ligação a DNA/genética
Modelos Animais de Doenças
Regulação para Baixo
Sinergismo Farmacológico
Seres Humanos
Masculino
Camundongos
Camundongos Endogâmicos NOD
Camundongos SCID
Camundongos Transgênicos
Proteínas Nucleares/genética
Proteínas Nucleares/metabolismo
Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo
Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia
Proteína A6 Ligante de Cálcio S100
Proteínas S100/genética
Fatores de Elongação da Transcrição/genética
Fator de Necrose Tumoral alfa/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aff1 protein, mouse); 0 (Aminopyridines); 0 (Anti-Allergic Agents); 0 (Cell Cycle Proteins); 0 (DNA-Binding Proteins); 0 (Nuclear Proteins); 0 (S100 Calcium Binding Protein A6); 0 (S100 Proteins); 0 (S100a6 protein, mouse); 0 (Transcriptional Elongation Factors); 0 (Tumor Necrosis Factor-alpha); 105504-00-5 (S100A6 protein, human); 150826-18-9 (AFF1 protein, human); BRL1C2459K (amlexanox)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170625
[St] Status:MEDLINE
[do] DOI:10.1158/0008-5472.CAN-16-2974


  9 / 4360 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28603114
[Au] Autor:Zhang M; Chen Z; Yang Y; Cheng H; Li C; He Q
[Ad] Endereço:Department of Oncology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
[Ti] Título:Pretreatment with different doses of dexamethasone in the prevention of docetaxel-induced hypersensitivity.
[So] Source:Pak J Pharm Sci;30(1):61-65, 2017 Jan.
[Is] ISSN:1011-601X
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:This study aimed to evaluate the efficacy and safety of dexamethasone pretreatment regimen with different doses in the prevention of docetaxel-induced hypersensitivity reaction (HSR). One hundred and sixty-two patients who had malignant tumors as determined by histology and/or cytology and received docetaxel treatments at least 2 cycles, were randomized into two groups. There were 90 patients in the study group and 72 patients in the control group. In the study group, patients received 4.5mg of oral dexamethasone once a day. Patients in the control group received 8 mg of dexamethasone twice a day. All patients received dexamethasone for 3 days, from the day before docetaxel treatment to the day after docetaxel treatment. The endpoints were hypersensitivity reaction (HSR) and other adverse effects, which were determined according to common terminology criteria for adverse event v3.0 (CTCAE 3.0). In the study group, 10 patients had HSRs (11.1%). While in the control group, 7 patients had HSRs (9.7%), and the main clinical symptoms of HSR were rash (3.1%), fever/chill (2.5%), angioedema (1.9%), chest discomfort (1.9%) and hypotension (0.6%). There was no statistically significant difference between these two groups (P=0.774). There was no significant difference in the incidence rate of adverse effect between patients in the study group and in the control group. Those adverse effects included neutropenia, decreased hemoglobin, nausea, vomiting, fatigue and fluid retention. Since no significant difference in the HSR incidence between these two groups has been found, 4.5mg of dexamethasone (qd) is as efficient and safe as 8mg (bid).
[Mh] Termos MeSH primário: Antialérgicos/administração & dosagem
Antineoplásicos/efeitos adversos
Dexametasona/administração & dosagem
Hipersensibilidade a Drogas/prevenção & controle
Taxoides/efeitos adversos
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Idoso
Antialérgicos/efeitos adversos
China
Dexametasona/efeitos adversos
Esquema de Medicação
Hipersensibilidade a Drogas/diagnóstico
Hipersensibilidade a Drogas/etiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Antineoplastic Agents); 0 (Taxoids); 15H5577CQD (docetaxel); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE


  10 / 4360 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28602936
[Au] Autor:Brozek JL; Bousquet J; Agache I; Agarwal A; Bachert C; Bosnic-Anticevich S; Brignardello-Petersen R; Canonica GW; Casale T; Chavannes NH; Correia de Sousa J; Cruz AA; Cuello-Garcia CA; Demoly P; Dykewicz M; Etxeandia-Ikobaltzeta I; Florez ID; Fokkens W; Fonseca J; Hellings PW; Klimek L; Kowalski S; Kuna P; Laisaar KT; Larenas-Linnemann DE; Lødrup Carlsen KC; Manning PJ; Meltzer E; Mullol J; Muraro A; O'Hehir R; Ohta K; Panzner P; Papadopoulos N; Park HS; Passalacqua G; Pawankar R; Price D; Riva JJ; Roldán Y; Ryan D; Sadeghirad B; Samolinski B; Schmid-Grendelmeier P; Sheikh A; Togias A; Valero A; Valiulis A; Valovirta E; Ventresca M
[Ad] Endereço:Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: jan.l.brozek@gmail.com.
[Ti] Título:Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.
[So] Source:J Allergy Clin Immunol;140(4):950-958, 2017 Oct.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. OBJECTIVE: We sought to provide a targeted update of the ARIA guidelines. METHODS: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. RESULTS: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H -antihistamines, intranasal H -antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. CONCLUSIONS: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.
[Mh] Termos MeSH primário: Antialérgicos/uso terapêutico
Asma/prevenção & controle
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Criança
Tomada de Decisão Clínica
Prática Clínica Baseada em Evidências
Seres Humanos
Qualidade de Vida
Rinite Alérgica/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Histamine H1 Antagonists)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE



página 1 de 436 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde